Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — This section highlights selected specific new recommendations and/or updates that we anticipate may change usual clinical practice. Practice Changing UpDates focus on changes that may have significant and broad impact on practice, and therefore do not represent all updates that affect practice. These Practice Changing UpDates, reflecting important changes to UpToDate over the past year, are presented chronologically, and are discussed in greater detail in the identified topic reviews.
ONCOLOGY, ADULT PRIMARY CARE (July 2016)
Duration of adjuvant endocrine therapy for breast cancer
●For postmenopausal women with nonmetastatic hormone receptor-positive breast cancer who have completed a five-year course of an aromatase inhibitor (AI), we suggest continuing the AI for an additional five years (Grade 2A).
For postmenopausal women receiving adjuvant treatment with an aromatase inhibitor (AI) for hormone-positive breast cancer, the standard duration of treatment has been five years. However, data from the MA17R trial demonstrated that a longer course of treatment improves disease-free survival (DFS) . Among approximately 1900 postmenopausal women who had completed four and a half to six years of therapy with an AI, treatment for an additional five years improved five-year DFS relative to those who received placebo (95 versus 91 percent). There was no difference between the groups in regards to overall survival. Bone-related toxic effects were more frequent among those receiving extended treatment. Based on these results, we now offer an additional five years of treatment to those who have completed five years of AI therapy. However, it is reasonable for women with low risk of recurrence who are concerned about the risks and toxicities of extended treatment to omit extended treatment after a risk-benefit discussion. (See "Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer", section on 'Duration of endocrine treatment'.)
ONCOLOGY (June 2016)
Choice of adjuvant chemotherapy for resected pancreatic cancer
●Following resection of pancreatic cancer, we suggest six months of combination chemotherapy with gemcitabine plus capecitabine rather than gemcitabine monotherapy for most patients (Grade 2B). However, therapy with gemcitabine alone (or, where available, S-1) is a reasonable option, particularly for patients with a borderline performance status or a comorbidity profile that precludes intensive therapy.
Adjuvant chemotherapy is recommended for all patients with resected pancreatic cancer. The standard approach has been gemcitabine monotherapy or, where available, S-1 alone. The benefit of a two-drug regimen was tested in the ESPAC-4 trial, which randomly assigned 730 patients with resected pancreatic adenocarcinoma to six months of gemcitabine with or without capecitabine . In a preliminary report presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), combination therapy was associated with significantly longer median overall survival (28 versus 25.5 months), and twice as many patients remaining alive at five years (19 versus 9). Severe diarrhea, hand-foot syndrome, and neutropenia were all significantly more common with combined therapy.
For most patients we suggest six months of combination chemotherapy with gemcitabine plus capecitabine rather than gemcitabine monotherapy after resection of pancreatic cancer. However, therapy with gemcitabine or S-1 alone remains a reasonable option, particularly for patients with a borderline performance status or a comorbidity profile that precludes intensive therapy. (See "Treatment for potentially resectable exocrine pancreatic cancer", section on 'Gemcitabine plus capecitabine'.)
ONCOLOGY (May 2016)
No survival benefit from chemoradiotherapy after initial chemotherapy for locally advanced pancreatic cancer
●For most patients with locally advanced pancreatic cancer who are not considered candidates for surgical exploration after initial chemotherapy, we suggest continued chemotherapy rather than chemoradiotherapy (Grade 2B). However, for patients in whom resection is being considered, chemoradiotherapy is still advised in an attempt to increase the likelihood of a complete resection.
There is no consensus as to the best approach for patients with locally advanced pancreatic cancer. Given that initial chemoradiotherapy (CRT) has not demonstrated a consistent survival benefit, and that up to one-third of patients develop overt metastases during the initial phase of treatment, it had been hoped that reserving CRT for patients without metastases after initial chemotherapy would improve survival. However, data from the randomized LAP-07 trial suggest no survival benefit from CRT compared with continued systemic chemotherapy alone, at least for patients treated initially with gemcitabine monotherapy .
For patients who do not progress following initial chemotherapy, subsequent therapy depends on whether the patient is a candidate for resection. For patients in whom resection is being considered, we continue to suggest combined treatment with external beam radiotherapy plus concomitant low-dose fluorouracil (eg, 200 mg/m2 daily), in an attempt to increase the rate of complete (R0) resection. For most patients with truly unresectable tumors following initial chemotherapy, we now suggest continued chemotherapy rather than CRT. However, CRT may be appropriate for selected patients, such as those with localized disease and a good performance status who cannot tolerate further chemotherapy. (See "Initial chemotherapy and radiation for nonmetastatic locally advanced unresectable and borderline resectable exocrine pancreatic cancer".)
INFECTIOUS DISEASES (May 2016)
Option for shortened MDR-TB regimen in updated WHO guidelines
●Consistent with WHO updated guidelines for patients with multidrug-resistant tuberculosis (MDR-TB), we suggest a shortened 9 to 12-month MDR-TB regimen for nonpregnant patients who have no extrapulmonary disease, an isolate known to be susceptible to fluoroquinolones and injectable antituberculous agents, and no prior exposure to second-line agents for more than one month (Grade 2C).
The conventional treatment regimen for multidrug-resistant tuberculosis (MDR-TB) consists of a fluoroquinolone, an injectable agent, and at least two other core second-line agents for a total duration of 20 to 26 months. Updated World Health Organization (WHO) guidelines present the option of a shortened regimen for nonpregnant patients with MDR-TB who have no extrapulmonary disease, an isolate known to be susceptible to fluoroquinolones and injectable antituberculous agents, and no prior exposure to second-line agents for more than one month . The shortened regimen consists of an intensive phase (four to six months of high-dose isoniazid, ethambutol, pyrazinamide, gatifloxacin [or moxifloxacin], kanamycin, prothionamide, and clofazimine) followed by a continuation phase (five months of ethambutol, pyrazinamide, gatifloxacin [or moxifloxacin], and clofazimine). Support for this regimen comes in part from a large study from Bangladesh that reported high rates of favorable bacteriologic outcomes with a similar 9 to 12-month regimen . The new WHO guidance also indicates that patients with rifampin monoresistance should be treated as for MDR-TB. Patients with known or suspected MDR-TB who do not meet criteria for the shortened MDR-TB regimen should be treated with the conventional regimen. (See "Diagnosis, treatment, and prevention of drug-resistant tuberculosis", section on 'General principles'.)
CARDIOVASCULAR MEDICINE (April 2016)
Surgical revascularization in patients with coronary disease and left ventricular systolic dysfunction
●For patients with ischemic cardiomyopathy (LVEF 35 percent or less) and coronary artery disease that is amenable to surgical revascularization, we suggest the combination of surgical revascularization and medical therapy rather than medical therapy alone (Grade 2B). Medical therapy alone is a reasonable option for patients who prioritize concerns about early CABG-associated morbidity and a small risk of early mortality over an overall decrease in longer-term mortality.
Most observational studies suggest that surgical revascularization in patients with ischemic cardiomyopathy (left ventricular ejection fraction [LVEF] of 35 percent or less) improves survival compared with medical therapy. Previously reported five-year outcomes of the randomized Surgical Treatment for Ischemic Heart Failure (STICH) trial comparing surgical revascularization with medical therapy alone showed a trend toward reduced mortality following surgical revascularization, but this primary outcome did not achieve statistical significance. An updated report, the STICH Extension Study (STICHES), extended the follow-up to a median of 9.8 years and found a significant 7 percent absolute reduction in total mortality for patients who underwent surgical revascularization . On the basis of this new evidence, we have revised our previous suggestion for initial management with medical therapy alone for most patients with LVEF 35 percent or less and coronary artery disease amenable to coronary artery bypass graft (CABG) surgery. For such patients, we now suggest the combination of surgical revascularization and medical therapy rather than medical therapy alone. This suggestion is based primarily on the long-term absolute reduction in mortality over the 10 years following CABG surgery. Based on the small but nontrivial early mortality risk associated with CABG surgery as well as other post-CABG morbidities, patients may also reasonably choose medical therapy as the initial treatment option. (See "Diagnosis and management of ischemic cardiomyopathy", section on 'Randomized trials'.)
INFECTIOUS DISEASES, ADULT PRIMARY CARE, FAMILY MEDICINE, EMERGENCY MEDICINE, HOSPITAL MEDICINE (March 2016)
Indications for antibiotics in the management of skin abscess
●We suggest antibiotic therapy as adjunctive therapy to incision and drainage for patients with a skin abscess that is ≥2 cm (Grade 2B).
The emergence of methicillin-resistant Staphylococcus aureus (MRSA) has raised uncertainty regarding the role of antimicrobial therapy for treatment of skin abscess following incision and drainage. In a randomized trial including 1220 patients >12 years of age (median 35 years) with drained skin abscess (≥2 cm in diameter) comparing trimethoprim sulfamethoxazole (TMP-SMX, 320 mg/1600 mg twice daily) with placebo, the cure rate 7 to 14 days after treatment was higher in the TMP-SMX group (80.5 versus 73.6 percent); wound cultures were positive for MRSA in 45 percent of cases . Based on these findings, abscess size ≥2 cm in diameter is a useful threshold for guiding decisions regarding use of antibiotic therapy for adjunctive treatment of skin abscess.
Additional factors for which we recommend antibiotic therapy include the presence of multiple lesions, extensive surrounding cellulitis, associated comorbidities or immunosuppression, signs of systemic infection, or inadequate clinical response to incision and drainage alone; we suggest antibiotic therapy for patients with an indwelling device or high risk for transmission of S. aureus to others. For otherwise healthy patients with none of these factors, we suggest not administering antimicrobial therapy. (See "Skin abscesses, furuncles, and carbuncles", section on 'Role of antibiotics'.)
HEMATOLOGY (March 2016, Modified March 2016)
Ibrutinib in older adults with newly diagnosed CLL
●For older adults with symptomatic CLL, we suggest single agent ibrutinib as initial treatment, rather than chlorambucil plus a novel anti-CD20 monoclonal antibody (obinutuzumab or ofatumumab) (Grade 2B).
Ibrutinib is commonly used for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and for the initial treatment of patients with CLL who carry a deletion in chromosome 17. Until now, there was little data regarding its use in other patients with previously untreated disease. In a phase III trial (RESONATE-2), 269 older adults with previously untreated CLL were randomly assigned to initial therapy with ibrutinib or chlorambucil . Ibrutinib was better tolerated and resulted in higher response rates and superior rates of progression-free and overall survival at two years. These results led to the approval of ibrutinib by the US Food and Drug Administration for the initial treatment of CLL . Ibrutinib is now our preferred therapy for previously untreated older adults with CLL. We continue to use fludarabine-based therapies for younger patients. (See "Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia", section on 'Ibrutinib'.)
PULMONOLOGY AND CRITICAL CARE, HEMATOLOGY, ADULT PRIMARY CARE, FAMILY MEDICINE, EMERGENCY MEDICINE, HOSPITAL MEDICINE (March 2016)
Agent selection for anticoagulation in venous thromboembolism
●For long-term anticoagulation for venous thromboembolism in most nonpregnant patients who do not have severe renal insufficiency or active cancer, we suggest a direct oral anticoagulant (ie, apixaban, edoxaban, rivaroxaban, or dabigatran) rather than other agents (Grade 2B).
Guidelines for the treatment of acute venous thromboembolism (VTE) were issued by The American College of Chest Physicians (ACCP) . Compared with earlier versions of the guidelines, the direct oral anticoagulants (DOACs) apixaban, edoxaban, rivaroxaban, or dabigatran are now the preferred agents for long-term anticoagulation in patients who are not pregnant and do not have active cancer or severe renal insufficiency. This preference was based upon randomized trials that consistently reported similar efficacy, a lower bleeding risk, and improved convenience when compared with warfarin. We agree with this preference for DOACs in patients with acute VTE, understanding that choosing among anticoagulants frequently depends upon availability and cost as well as patient comorbidities and preferences. (See "Venous thromboembolism: Anticoagulation after initial management", section on 'Selection of agent'.)
HEMATOLOGY, NEUROLOGY, PEDIATRICS (March 2016)
Stroke prevention in sickle cell disease
●For children with sickle cell disease and increased risk for a first ischemic stroke based on transcranial Doppler measurements, who have received chronic transfusion therapy for at least two years and who meet criteria for hydroxyurea therapy based on the TWiTCH trial, we suggest transition to hydroxyurea (Grade 2C).
Individuals with sickle cell disease (SCD) are at risk for ischemic and hemorrhagic stroke. Transcranial Doppler (TCD) measures blood flow rate in intracranial arteries and is used to assess stroke risk in children with SCD. Children with increased TCD velocities are treated with chronic prophylactic transfusions to reduce the risk of ischemic stroke. The recently published TWiTCH trial (TCD With Transfusions Changing to Hydroxyurea) randomly assigned 121 children who had completed a period of chronic transfusions and who met study criteria (related to hemoglobin S levels with transfusion, TCD velocities, magnetic resonance angiographic findings, ability to comply with treatment and monitoring, and response to hydroxyurea) to transition to hydroxyurea therapy or to continue transfusions . After approximately two years of follow-up, TCD velocities were similar in both groups and there were no strokes in either group. For children who would have met criteria for the TWiTCH trial, we suggest transitioning to hydroxyurea after two or more years of chronic transfusion, with transfusions tapered and hydroxyurea dosing gradually increased during the transition, as done in the trial. We continue to recommend chronic transfusions for all patients with SCD who have had an ischemic stroke (ie, for secondary prevention). (See "Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Chronic transfusion followed by transition to hydroxyurea'.)
OBSTETRICS, GYNECOLOGY AND WOMEN'S HEALTH, FAMILY MEDICINE (February 2016)
Antenatal steroids at 34 to 37 weeks for pregnancies at high risk of preterm birth
●For pregnant women who will deliver at 340/7ths to 366/7ths weeks of gestation by scheduled cesarean, we suggest administration of a first course of antenatal corticosteroids (Grade 2C).
Antenatal corticosteroid therapy at 23 to 34 weeks of gestation for women at risk for preterm delivery reduces the incidence and severity of respiratory distress syndrome in offspring delivered within seven days of administration. Steroids have not been administered after 34 weeks because studies have not demonstrated a benefit, although data have been sparse. Recently, the Antenatal Late Preterm Steroids (ALPS) Trial randomly assigned women at 340/7ths to 365/7ths weeks of gestation at high risk for late preterm birth to receive a first course of antenatal betamethasone or placebo and found that the frequency of a composite outcome of neonatal respiratory problems was reduced in the betamethasone group . Based on these data, we believe offering a first course of antenatal corticosteroids to patients scheduled for cesarean delivery at 340/7ths to 366/7ths weeks is reasonable. We would not administer a first course of steroids to women at 340/7ths to 366/7ths weeks planning vaginal delivery as transient tachypnea of the newborn is less common after labor and vaginal birth. For women in whom delivery at 340/7ths to 366/7ths is uncertain (eg, threatened preterm labor), we would not administer a course of steroids because of the potential for long-term harm with no benefit if the patient does not deliver preterm. For women at 340/7ths to 366/7ths weeks who received a course of antenatal corticosteroids earlier in pregnancy, we would not administer a second course as the benefits and risks have not been studied in this population. This approach limits late preterm in utero steroid exposure to pregnancies certain to deliver preterm and with neonates at most risk for experiencing serious respiratory problems from transient tachypnea of the newborn. We do not administer steroids to women undergoing scheduled cesarean delivery at ≥37 weeks: the overall risk of respiratory illness at this gestational age is low and rarely serious. (See "Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery", section on 'After 34 weeks'.)
ADULT PRIMARY CARE, FAMILY MEDICINE, GERIATRICS, CARDIOVASCULAR MEDICINE, ENDOCRINOLOGY AND DIABETES (January 2016)
Screening for diabetes mellitus
●For adults with hypertension or hyperlipidemia, as well as for those aged 40 to 70 years with BMI ≥25 kg/m2, we suggest screening for type 2 diabetes as part of cardiovascular risk assessment (Grade 2C).
Although it has not been firmly established that screening for type 2 diabetes improves long-term outcomes, well-established treatments for diabetes can reduce progression to microvascular disease and early identification of diabetes allows interventions to prevent or limit cardiovascular disease. The US Preventive Services Task Force (USPSTF) has issued new recommendations for diabetes screening. Previously, the USPSTF only recommended screening for diabetes in adults with hypertension, but the new guideline recommends screening for diabetes as part of cardiovascular risk assessment in adults aged 40 to 70 years with body mass index (BMI) ≥25 kg/m2 . The USPSTF suggests screening every three years based on limited evidence. We agree with the new USPSTF guideline and also suggest diabetes screening for adults with hypertension or hyperlipidemia. A fasting plasma glucose (FPG) and/or a glycated hemoglobin (A1C) are the preferred screening tests. (See "Screening for type 2 diabetes mellitus", section on 'A suggested approach'.)
EMERGENCY MEDICINE (ADULT AND PEDIATRIC) (January 2016)
Epinephrine for the treatment of fluid-refractory, cold septic shock in infants and children
●We suggest that infants and children with fluid-refractory cold shock receive epinephrine infusions (initial starting dose 0.05 to 0.1 mcg/kg/minute, titrate to response up to 1.5 mcg/kg/minute) rather than dopamine (Grade 2C).
The 2009 American College of Critical Care Medicine (ACCM) pediatric sepsis guidelines recommended dopamine as the first-line agent for the treatment of fluid-refractory septic shock in patients with signs of vasoconstriction or "cold" shock (eg, cold extremities and diminished peripheral pulses). However, in a single-center randomized trial of 120 infants and children (1 month to 15 years of age) undergoing treatment for fluid-refractory septic shock in a pediatric intensive care unit (88 percent with cold shock), patients who received infusions of dopamine rather than epinephrine had significantly higher mortality (21 versus 7 percent) and more healthcare-associated infections (29 versus 2 percent) . Based on these findings, we now suggest that infants and children with fluid-refractory, hypotensive, cold septic shock receive infusions of epinephrine rather than dopamine. Epinephrine infusions are initiated at a dose of 0.05 to 0.1 mcg/kg/minute and titrated to response up to 1.5 mcg/kg/minute. The 2009 ACCM pediatric sepsis guidelines are undergoing review. (See "Septic shock: Rapid recognition and initial resuscitation in children", section on 'Cold shock'.)
NEPHROLOGY AND HYPERTENSION, ADULT PRIMARY CARE, CARDIOVASCULAR MEDICINE, FAMILY MEDICINE, GERIATRICS (November 2015, Modified December 2015)
SPRINT trial on goal blood pressure
●In hypertensive patients with characteristics similar to those enrolled in the SPRINT trial (age 50 years or older with systolic blood pressure 130 to 180 mmHg and an additional risk factor for cardiovascular disease other than diabetes, proteinuric chronic kidney disease, or stroke), as well as for hypertensive patients with diabetes, we now recommend the same lower goal blood pressure, although the strength of recommendation and the quality of evidence varies depending on patient group and the method used to measure blood pressure:
● If blood pressure is measured using an automated oscillometric device that averages multiple readings with the patient resting alone in a room, we recommend targeting a blood pressure of 120-125/<90 mmHg rather than <140/<90 mmHg (Grade 1A). For diabetic patients, we suggest targeting this same goal blood pressure (Grade 2B).
● If other methods of blood pressure measurement are used, we recommend targeting a blood pressure of 125-130/<90 mmHg rather than <140/<90 mmHg (Grade 1B). For diabetic patients, we suggest targeting this same goal blood pressure (Grade 2B).
Goal blood pressure in most hypertensive patients had been <140/90 mmHg, or <150/90 mmHg in older adults. The potential benefit of lowering the systolic blood pressure goal in nondiabetic older adults with risk factors for cardiovascular disease or with chronic kidney disease was evaluated in the Systolic Blood Pressure Intervention Trial (SPRINT), a multicenter, randomized, open-label trial performed in 9361 hypertensive patients in the United States . Patients were randomly assigned to a standard treatment group (target systolic pressure <140 mmHg) or an intensive treatment group (target systolic pressure <120 mmHg); the diastolic goal in both groups was <90 mmHg. Blood pressure during the trial was measured using automated oscillometric blood pressure (AOBP) and not using manual (ausculatory) blood pressure (perhaps more commonly used in routine practice), typically yielding readings 5 to 10 mm lower than with manual measurement. In the SPRINT trial, consecutive automated blood pressure readings were taken with the patient at rest and averaged. After a median of 3.26 years, intensive as compared with standard treatment reduced the rate of the primary end point, a composite of myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death (5.2 versus 6.8 percent), and also reduced mortality (3.3 versus 4.5 percent). Intensive treatment increased the rates of acute kidney injury, syncope, and hyponatremia, but not orthostatic hypotension or falls resulting in hospitalization.
As a result of the SPRINT trial, UpToDate now recommends lower systolic pressure goals (depending on the method of measurement) for nondiabetic adults 50 years and older at high risk for cardiovascular events, and suggests such goals for patients with diabetes. Goals for other groups, including those with proteinuric chronic kidney disease, have not changed based upon the SPRINT data. A trial examining goal blood pressure for patients with diabetes is likely to report findings for this population in 2016. (See "What is goal blood pressure in the treatment of hypertension?", section on 'Benefit according to overall cardiovascular risk' and "Goal blood pressure in patients with cardiovascular disease or at high risk".)
INFECTIOUS DISEASES (August 2015, Modified November 2015)
Adjunctive glucocorticoids for adults with severe community-acquired pneumonia
●For hospitalized patients with community-acquired pneumonia (CAP) who require intensive care unit admission, we recommend adjunctive glucocorticoids (Grade 1B). Additionally, for other hospitalized patients with CAP, we suggest adjunctive glucocorticoids (Grade 2B). We are more likely to give glucocorticoids to more severely ill patients and we are less likely to give glucocorticoids to patients at increased risk of adverse effects.
For hospitalized patients with community-acquired pneumonia (CAP), glucocorticoids as adjunctive therapy to antibiotics have the potential to reduce the inflammatory response and decrease morbidity. A 2015 meta-analysis of randomized trials that included hospitalized patients with CAP suggested a modest mortality benefit for adjunctive glucocorticoids . A reduction in all-cause mortality was of borderline statistical significance (relative risk [RR] 0.67, 95% CI 0.45-1.01; risk difference 2.8 percent). Rates of mechanical ventilation and acute respiratory distress syndrome were decreased, as were time to clinical stability and duration of hospitalization; rates of hyperglycemia requiring treatment increased.
For hospitalized patients with CAP who require intensive care unit admission, we recommend adjunctive glucocorticoids. For other hospitalized patients with CAP, we suggest adjunctive glucocorticoids. Clinicians should make the decision whether or not to give glucocorticoids on a case-by-case basis, especially in patients with an elevated risk of adverse effects. Limited evidence suggests that infections caused by certain pathogens (eg, influenza virus, Aspergillus spp) may be associated with worse outcomes in the setting of glucocorticoid use [17,18]; given these concerns, we avoid adjunctive glucocorticoids if one of these pathogens is detected. (See "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Glucocorticoids'.)
HEMATOLOGY (October 2015)
Dabigatran reversal agent approved
●For patients anticoagulated with dabigatran who are at an imminent risk of death from bleeding, in addition to treatment with an antifibrinolytic agent and drug removal with oral charcoal and/or hemodialysis, we suggest administering idarucizumab (Grade 2C). For those for whom idarucizumab is not available, we suggest using an activated prothrombin complex concentrate (aPCC; eg, factor eight inhibitor bypassing agent [FEIBA]) (Grade 2C).
The lack of a specific reversal agent for the direct thrombin inhibitor dabigatran has been a persistent concern in its use for patients with atrial fibrillation or venous thromboembolism. Idarucizumab (Praxbind) is a reversal agent for dabigatran that was approved by the US Food and Drug Administration in October 2015 to reverse dabigatran effect in the setting of life-threatening or uncontrolled bleeding or emergency surgery [19,20]. Approval was based on studies in healthy volunteers and an interim analysis of the RE-VERSE AD trial, which included a cohort of 90 older adult patients who had clinically significant bleeding or the need for an urgent invasive procedure while taking dabigatran for atrial fibrillation . Idarucizumab produced rapid normalization of clotting times and/or surgical hemostasis; there were five thrombotic events and 18 deaths. Without a control group it is unclear how these outcomes would compare with similar patients who did not receive idarucizumab. For patients with life-threatening bleeding, we would use idarucizumab, if available, along with other measures to decrease bleeding risk, but we would not combine idarucizumab with procoagulant products such as an activated prothrombin complex concentrate (aPCC). Idarucizumab is an antibody-based therapy and does not have known activity against direct factor Xa inhibitors or other anticoagulants. (See "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Dabigatran reversal'.)
ADULT PRIMARY CARE, FAMILY MEDICINE, CARDIOVASCULAR MEDICINE, GERIATRICS, HOSPITAL MEDICINE, ENDOCRINOLOGY AND DIABETES, NEUROLOGY (September 2015)
PCSK9 antibodies for cardiovascular risk reduction
●In patients with stable cardiovascular disease (CVD) at very high risk for CVD events (expected 10-year event rate of greater than 25 percent), such as those in the proposed NCEP guidelines, we suggest high-intensity statin therapy plus a PCSK9-ab rather than targeting a goal LDL-C (Grade 2B). Other experts, including other authors for UpToDate, would make decisions about adding medications to statin therapy based on goal LDL-cholesterol.
In very high-risk patients who do not tolerate any statin regimen, we recommend treatment with a PCSK9-ab (Grade 1B). In higher-risk patients who do not tolerate any statin regimen, we suggest treatment with a PCSK9-ab (Grade 2B).
Monoclonal antibodies that inhibit proprotein convertase subtilisin kexin 9 (PCSK9-abs) reduce LDL-cholesterol levels by as much as 70 percent. Randomized trials with small numbers of events and limited follow-up suggest that at least two of these agents, alirocumab and evolocumab, substantially reduce cardiovascular events and mortality when used for secondary prevention, both as monotherapy and in combination with statin therapy [22,23]. (See "Lipid lowering with drugs other than statins and fibrates", section on 'PCSK9 inhibitors'.)
PCSK9-abs are becoming available for clinical use. The agents require subcutaneous injection every two to four weeks and are very expensive. While awaiting greater experience with these agents, we would use them in situations where the expected reductions in cardiovascular events are likely to outweigh any as yet unknown adverse events from a new therapy. These include using them in combination with statin therapy in very high-risk patients with stable cardiovascular disease, such as those in the proposed NCEP guidelines (table 1), and as monotherapy in very high-risk and higher-risk patients who are intolerant of statin therapy. Other experts, including other authors for UpToDate, would make decisions about adding medications to statin therapy based on goal LDL-cholesterol. (See "Intensity of lipid lowering therapy in secondary prevention of cardiovascular disease", section on 'Stable CVD' and "Treatment of lipids (including hypercholesterolemia) in secondary prevention", section on 'Summary and recommendations'.)
PULMONARY AND CRITICAL CARE MEDICINE, CARDIOVASCULAR MEDICINE (September 2015)
Combination therapy with ambrisentan and tadalafil for pulmonary arterial hypertension
●For most patients with group 1 pulmonary arterial hypertension who have class II or III symptoms, we suggest ambrisentan and tadalafil rather than other combinations or single agent therapy (Grade 2B).
Typically, patients with group 1 pulmonary arterial hypertension (PAH) who have World Health Organization (WHO) class II or III symptoms are treated with single agent advanced therapy. In a randomized trial, the combination of ambrisentan (a selective endothelin receptor A antagonist) and tadalafil (a cyclic GMP phosphodiesterase type 5 [PDE5] inhibitor) was associated with a significant reduction in the rate of clinical failure when compared with either agent alone . The improved clinical outcome was driven primarily by reduction in the rate of hospitalizations for progressive PAH, a factor that portends poor prognosis, rather than by improved survival or WHO functional class. We now suggest this combination as first-line therapy for newly diagnosed patients with group 1 PAH and functional class II or III symptoms, who have either a negative vasoreactivity test or who are vasoreactive but fail to respond to calcium channel blocker therapy (algorithm 1). (See "Treatment of pulmonary hypertension in adults", section on 'Combination therapy'.)
GASTROENTEROLOGY AND HEPATOLOGY (September 2015)
Mechanical bowel preparation and oral antibiotics prior to elective colon surgery
●For patients undergoing elective colon resection, we suggest mechanical bowel preparation combined with oral antibiotics rather than mechanical bowel preparation alone or no preparation (Grade 2C).
Traditionally, mechanical bowel preparation was used with oral antibiotics to prepare for all elective colon surgeries. After several randomized trials reported no benefit from mechanical bowel preparation (MBP) without antibiotics, colon resection without preoperative bowel preparation and without oral antibiotics became widespread. A retrospective study of data from over 8000 patients undergoing colorectal resection found that MBP combined with oral antibiotics, compared with MBP alone, was associated with lower rates of anastomotic leak, and that MBP, with or without antibiotics, was associated with lower rates of surgical site infection and postoperative ileus compared with no preparation prior to surgery . A subsequent meta-analysis of seven randomized trials reached a similar conclusion . One drawback is a potential increase in the rate of Clostridium difficile infection for patients treated with oral antibiotics.
Thus, for patients undergoing elective colon surgeries, we suggest mechanical bowel preparation combined with oral antibiotics. Mechanical bowel preparation is usually accomplished with polyethylene glycol solution and is followed by oral antibiotics such as neomycin and erythromycin base. Administering oral antibiotics in the absence of mechanical bowel preparation is of unproven benefit and is not advised. (See "Overview of colon resection", section on 'Bowel preparation'.)
PEDIATRICS (August 2015)
Lumacaftor-ivacaftor for patients with cystic fibrosis and homozygous for the F508del mutation
●For patients with cystic fibrosis 12 years of age or older who are homozygous for F508del, we suggest using lumacaftor-ivacaftor (Grade 2B). The high cost of this therapy may affect individual and societal decisions about its use.
Lumacaftor-ivacaftor is a combination of two cystic fibrosis transmembrane conductance regulator (CFTR) modulators that was approved by the US Food and Drug Administration in July 2015. The approval was based on two randomized trials with 1100 homozygous F508del subjects ages 12 years and older . Compared with placebo, the groups receiving lumacaftor-ivacaftor for 24 weeks had small but statistically significant improvements in percent predicted FEV1 and body mass index (BMI), and reduced frequency of pulmonary exacerbations. Adverse effects included chest discomfort and dyspnea and were more common in subjects with worse baseline lung function. The improvement in absolute FEV1 from baseline compared with placebo (2.6 to 4 percentage points) is similar in magnitude to that achieved by treatments with inhaled dornase alfa or tobramycin. We suggest use of lumacaftor-ivacaftor for F508del homozygotes because it has modest short-term benefits and is tolerated by most patients. However, the expense of the drug and drug-drug interactions should be considered when deciding on its use. (See "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Efficacy'.)
ONCOLOGY (July 2015)
Extended dosing interval for zoledronic acid in patients with bone metastases
●For most patients with breast or prostate cancer metastatic to bone who are not candidates for denosumab and who have neither highly symptomatic nor extensive bone metastases, we suggest administration of zoledronic acid every 12 weeks rather than every four weeks (Grade 2B).
Osteoclast inhibitors are indicated in patients with metastatic bone disease to reduce the frequency of skeletal-related events (SREs). For most patients, denosumab is preferred, but a bisphosphonate such as zoledronic acid is a reasonable alternative. The approved dosing interval for zoledronic acid is every three to four weeks. The non-inferiority of less frequent administration was shown in CALGB (Alliance) trial 70604, which randomly assigned 1822 patients with bone metastases (833 with breast cancer, 674 with prostate cancer, 270 with myeloma, and 45 with other malignancies) to the same dose of zoledronic acid administered every four or every 12 weeks for two years, starting with the first dose . In a preliminary report presented at the 2015 annual American Society of Clinical Oncology (ASCO) meeting, there was no significant difference in the proportion of patients with at least one SRE, in the time to the first SRE, in pain scores, or in the frequency or severity of adverse events.
Based on these findings, we suggest dosing of zoledronic acid every 12 rather than every four weeks for most patients with metastatic breast and prostate cancer if a bisphosphonate is chosen over denosumab. However, we still prefer every-four-week dosing, at least initially, for patients with breast or prostate cancer who have extensive or highly symptomatic bone metastases. There are insufficient data to recommend a change in dosing interval for patients with bone metastases from solid tumors other than breast and prostate cancer, and we continue to treat these patients with every-four-week zoledronic acid, if a bisphosphonate is chosen. However, there may be circumstances (eg, no rapid bone resorption, limited burden of bone metastases, high likelihood of response to systemic anticancer treatment) where an extended dosing interval might be appropriate if it is compatible with the patient’s goals of care. (See "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Dosing interval'.)
HEMATOLOGY (July 2015)
Bridging anticoagulation in patients who require warfarin interruption for surgery
●For most patients who require interruption of warfarin for surgery, we suggest not using perioperative bridging anticoagulation (Grade 2B). We feel more strongly about avoiding bridging the lower the thromboembolic risk and the higher the risk of bleeding.
We continue to bridge individuals with a high thromboembolic risk.
Perioperative management of a patient receiving an anticoagulant is challenging because the risks of bleeding and thromboembolism are both increased. Not all patients require anticoagulant interruption. For those who do require interruption of their anticoagulant, the risks and benefits of bridging (use of a short-acting parenteral agent, typically a low molecular weight [LMW] heparin) have been unclear. The BRIDGE trial randomly assigned patients with atrial fibrillation to receive the LMW heparin dalteparin or placebo during warfarin interruption for surgery or an invasive procedure . The risk of thromboembolism was similar in those who received dalteparin or placebo for bridging. However, patients bridged with dalteparin had a greater risk of bleeding. As a result of the BRIDGE trial, we suggest not using bridging for most individuals who require warfarin interruption. We continue to suggest bridging in certain high-risk individuals, including those with a mechanical mitral valve, thromboembolic event within the previous 12 weeks, atrial fibrillation and very high risk of stroke, recent coronary stenting, or previous thromboembolism during interruption of chronic anticoagulation. (See "Perioperative management of patients receiving anticoagulants", section on 'Whether to use bridging'.)
CARDIOVASCULAR MEDICINE (July 2015)
Angiotensin receptor-neprilysin inhibitor for heart failure with reduced ejection fraction
●We suggest use of sacubitril-valsartan in place of the ACE inhibitor (or single agent ARB) component of therapy, in patients with stable mild to moderate HFrEF (LVEF ≤40 percent), an elevated natriuretic peptide level or hospitalization for HF in the past 12 months, a systolic blood pressure ≥100 mm Hg, and eGFR ≥30 mL and who have tolerated high-doses of ACE inhibitor or ARB therapy for ≥4 weeks (Grade 2B).
Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved in the United States by the US Food and Drug Administration for use in patients with chronic New York Heart Association (NYHA) functional class II to IV heart failure with reduced ejection fraction (HFrEF) . In a randomized trial, sacubitril-valsartan reduced mortality and morbidity compared with angiotensin converting enzyme (ACE) inhibitor therapy, when used in combination with other standard heart failure therapies. However, less than 1 percent of patients in the trial had NYHA class IV heart failure. We suggest use of sacubitril-valsartan in place of the ACE inhibitor (or single agent ARB) component of therapy, in patients with stable mild to moderate HFrEF (LVEF ≤40 percent), an elevated natriuretic peptide level or hospitalization for HF in the past 12 months, a systolic blood pressure ≥100 mm Hg, and eGFR ≥30 mL and who have tolerated high-doses of ACE inhibitor or ARB therapy for ≥4 weeks. This recommendation is likely to evolve with time as more data become available and experience with sacubitril-valsartan develops. (See "Use of angiotensin II receptor blocker and neprilysin inhibitor in heart failure with reduced ejection fraction", section on 'Indication'.)
- Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016.
- Neoptolemos JP, Palmer D, Ghaneh P, et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (abstr). J Clin Oncol 34, 2016 (suppl; abstr LBA4006). Abstract available online at http://meetinglibrary.asco.org/content/162546-176 (Accessed on June 14, 2016).
- Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315:1844.
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. WHO, Geneva 2016. http://www.who.int/tb/MDRTBguidelines2016.pdf?ua=1 (Accessed on May 17, 2016).
- Aung KJ, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18:1180.
- Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016; 374:1511.
- Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med 2016; 374:823.
- Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373:2425.
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205552s007lbl.pdf (Accessed on March 11, 2016).
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315.
- Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet 2016; 387:661.
- Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med 2016; 374:1311.
- Siu AL, U S Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2015; 163:861.
- Ventura AM, Shieh HH, Bousso A, et al. Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrine as First-Line Vasoactive Drugs in Pediatric Septic Shock. Crit Care Med 2015; 43:2292.
- SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373:2103.
- Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:519.
- Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 2015; 212:183.
- Parody R, Martino R, Sánchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009; 84:571.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery (Accessed on October 16, 2015).
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf (Accessed on October 19, 2015).
- Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373:511.
- Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:40.
- Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.
- Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:834.
- Kiran RP, Murray AC, Chiuzan C, et al. Combined preoperative mechanical bowel preparation with oral antibiotics significantly reduces surgical site infection, anastomotic leak, and ileus after colorectal surgery. Ann Surg 2015; 262:416.
- Chen M, Song X, Chen LZ, et al. Comparing Mechanical Bowel Preparation With Both Oral and Systemic Antibiotics Versus Mechanical Bowel Preparation and Systemic Antibiotics Alone for the Prevention of Surgical Site Infection After Elective Colorectal Surgery: A Meta-Analysis of Randomized Controlled Clinical Trials. Dis Colon Rectum 2016; 59:70.
- Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 2015; 373:220.
- Himelstein AL, Qin R, Novotny PJ, et al. CALGB 90604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dising of zoledronic acid in metastatic cancer (abstr). J Clin Oncol 33, 2015 (suppl; abstr 9501). Abstract available at http://meetinglibrary.asco.org/content/147845-156 (Accessed on July 09, 2015).
- Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373:823.
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf (Accessed on July 22, 2015).